pulmonary arterial hypertension

Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy
Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy
Fierce Biotech
Merck
Acceleron
clinical trials
sotatercept
PAH
pulmonary arterial hypertension
Flag link:
Here's What Lifted Arena Pharmaceuticals, Inc. Stock in September
Here's What Lifted Arena Pharmaceuticals, Inc. Stock in September
Motley Fool
Arena Pharmaceuticals
ralinepag
PAH
pulmonary arterial hypertension
Flag link:
Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says
Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says
TheStreet.com
Arena Pharmaceuticals
ralinepag
PAH
pulmonary arterial hypertension
Flag link:
Arena takes a big step down the comeback trail with PhII success, shares rocket up
Arena takes a big step down the comeback trail with PhII success, shares rocket up
Endpoints
Arena Pharmaceuticals
PAH
clinical trials
pulmonary arterial hypertension
ralinepag
Flag link:
How Is United Therapeutics’ Remodulin Positioned in 2017?
How Is United Therapeutics’ Remodulin Positioned in 2017?
Market Realist
United Therapeutics
Remodulin
PAH
pulmonary arterial hypertension
Flag link:
EMA panel recommends that use of Actelion's Uptravi may continue
EMA panel recommends that use of Actelion's Uptravi may continue
Yahoo/Reuters
Europe
Actelion
Uptravi
pulmonary arterial hypertension
PAH
France
Flag link:
Actelion drug fails trial, denting revenue potential
Actelion drug fails trial, denting revenue potential
Yahoo/Reuters
Actelion
clinical trials
Opsumit
PAH
pulmonary arterial hypertension
Flag link:
United Therapeutics sees stepped-up competition and says it's 'a good thing'
United Therapeutics sees stepped-up competition and says it's 'a good thing'
Bizjournals.com
United Therapeutics
PAH
pulmonary arterial hypertension
Flag link:
Could an old Roche arthritis med become a pioneering PAH treatment?
Could an old Roche arthritis med become a pioneering PAH treatment?
BioPharma Dive
Roche
PAH
pulmonary arterial hypertension
tocilizumab
Actemra
Flag link:
Actelion sees Uptravi price of $160,000-170,000/patient
Actelion sees Uptravi price of $160,000-170,000/patient
Yahoo/Reuters
Actelion
Uptravi
PAH
pulmonary arterial hypertension
Flag link:
Actelion says selexipag to enter U.S. market in January
Actelion says selexipag to enter U.S. market in January
Yahoo/Reuters
Actelion
selexipag
Uptravi
PAH
pulmonary arterial hypertension
Flag link:
With Opsumit launch rolling, Actelion doesn't 'need' M&A: CEO
With Opsumit launch rolling, Actelion doesn't 'need' M&A: CEO
Fierce Pharma
Actelion
Opsumit
M&A
PAH
pulmonary arterial hypertension
Flag link:
Gilead Sciences Letairis Wins FDA Nod For PAH: Stock To Recover Soon
Gilead Sciences Letairis Wins FDA Nod For PAH: Stock To Recover Soon
Bidness, ETC
PAH
pulmonary arterial hypertension
FDA
Gilead Sciences
Letairis
Flag link:
Bellerophon shares skyrocket on high blood pressure drug study
Bellerophon shares skyrocket on high blood pressure drug study
Marketwatch
Bellerophon
PAH
Inopulse
clinical trials
pulmonary arterial hypertension
Flag link:
Actelion's Opsumit growth heralds smooth switch off aging Tracleer
Actelion's Opsumit growth heralds smooth switch off aging Tracleer
Fierce Pharma
Actelion
Opsumit
Tracleer
PAH
pulmonary arterial hypertension
Flag link:
Deep dive into Actelion's Uptravi data calms investors as FDA decision date nears
Deep dive into Actelion's Uptravi data calms investors as FDA decision date nears
Fierce Biotech
Actelion
Uptravi
PAH
pulmonary arterial hypertension
Flag link:
GSK and Gilead’s combination therapy: positive results in PAH
GSK and Gilead’s combination therapy: positive results in PAH
Pharmaphorum
GSK
Gilead Sciences
PAH
pulmonary arterial hypertension
Letairis
Adcirca
Flag link:
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status
Yahoo/Zacks.com
Arena Pharmaceuticals
APD811
orphan drugs
PAH
pulmonary arterial hypertension
Flag link:
Phase 4 Actelion Study Misses Primary Endpoint
Phase 4 Actelion Study Misses Primary Endpoint
Forbes
Actelion
Tracleer
pulmonary arterial hypertension
Flag link:
Actelion’s Lung Drug May Face Study Against Gilead Rival
Actelion’s Lung Drug May Face Study Against Gilead Rival
Bloomberg
Actelion
Gilead Sciences
Opsumit
Letairis
PAH
pulmonary arterial hypertension
Flag link:

Pages